Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis AG’s ‘biosimilar’ drug sale blocked by U.S. appeals court

(Reuters) – A U.S. appeals court has blocked the sale of Novartis AG’s recently approved “biosimilar” form of Neupogen, Amgen Inc’s blockbuster drug used to prevent infections in cancer patients. A lower court judge rejected Amgen’s request for an injunction. The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday, however, that the […]

Read More » Asthma Therapeutics Market to Reach $21.7 Billion by 2020, Says New GBI Research Report

WASHINGTON and NEW YORK and LONDON, May 7, 2015 /PRNewswire/ — As a leading provider of market research reports and solutions, is pleased to highlight a recent report by GBI Research, forecasting the asthma therapeutics market to hit $21.7 billion by 2020, a CAGR 2.4% over $18.4 billion in 2013. To view this report by […]

Read More »

J&J to consult ethicists on requests for experimental drugs

(Reuters) – Johnson & Johnson will become the first pharmaceutical company to formally seek advice from outside medical ethicists on “compassionate use” requests, in which desperate patients ask drugmakers to let them take an experimental medication, the company announced on Thursday. The ethicists’ recommendations will be advisory, with J&J making the decision. But the drugmaker […]

Read More »

Venezuela says probing drugmakers for improper use of hard currency

(Reuters) – Venezuela is investigating whether drug companies including Germany’s Merck KGaA and Bayer AG have improperly profited from subsidized foreign exchange amid growing medicine shortages, the country’s health minister said. Those firms have received a favorable exchange rate through Venezuela’s currency controls to produce or import price-controlled medication to treat chronic ailments such as […]

Read More »

EU watchdog disagrees with negative view on UniQure gene therapy

(Reuters) – European regulators do not agree with the negative view expressed by one adviser about the efficacy of UniQure’s drug Glybera, the Western world’s first gene therapy. The Dutch company said it had received a final assessment report from the European Medicines Agency’s Committee for Advanced Therapies (CAT) following doubts raised by the adviser, […]

Read More »

Emergency Physicians Are Not Likely To Prescribe Opioids To Discharged Patients

While some people visit primary care physicians when they’re in pain, others head to the emergency room. With emergency physicians wanting to provide pain relief to their patients, prescribing opioids to discharged patients may seem like the best option to some — but many physicians are refusing to jump the gun too soon. Published in the Annals of Emergency Medicine, a journal […]

Read More »

Gilead’s John C. Martin: One Breakthrough Drug After Another

In his 25-year-tenure at Gilead, first as research chief and then as the boss, Martin led the development of the most widely prescribed HIV pill and, last year, a treatment for the liver virus hepatitis C that can cure 90% of patients and generated $12 billion in revenue in its first year on the market. It […]

Read More »

GSK sees little prospect of U.S. generic Advair in 2016

A logo of GlaxoSmithKline Pharmaceuticals Ltd company is pictured outside its headquarters in Mumbai December 16, 2013. Reuters/Danish Siddiqui (Reuters) – After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics – but not just yet. Chief Executive Andrew Witty said on […]

Read More »

Under pressure, FDA to hold public meeting on off-label use

(Reuters) – The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their First Amendment right to free speech. The meeting, announced last month by FDA chief counsel Elizabeth Dickinson, comes as a bill […]

Read More »

The Cancer Drug Market Just Hit $100 Billion And Could Jump 50% In Four Years

The global market for cancer drugs has hit $100 billion in annual sales, and could reach $147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics, a unit of drug data provider IMS Health. This figure does not include discounts or rebates paid to insurers and government programs; IMS […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom